Evidence map›Paper›PMID 41381843›Full record

ArticleBritish journal of cancer2026

Sorafenib plus selective internal radiotherapy with

Grégoire Berthod, Christophe Cisarovsky, Tatiana Petrova, Laurent A Decosterd, Eva Choong, Dan Celestini, Michel A Cuendet, Sarah Boughdad, John O Prior, Jean-Yves Meuwly and 3 more

Registry-linked trialAbstract readClinical Trial, Phase I
PubMed Full text at PMC Publisher
In one paragraph

Article in British journal of cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT01893099 (Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma), which is not on this map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01893099 phase1completednot on this map

Sorafenib and Radioembolization With Sir-Spheres® for the Treatment of Metastatic Ocular Melanoma

TypeinterventionalSponsorCentre Hospitalier Universitaire VaudoisRan2013 to 2017Enrolled11ConditionsOcular MelanomaArmsSorafenib, Radioembolization with SIR-Spheres® (Yttrium Microspheres)
3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Grégoire BerthodMedical Oncology Service, Hôpital du Valais, Sion, Lausanne University Hospital, Lausanne, Switzerland. gregoire.berthod@hopitalvs.ch.ORCID http://orcid.org/0009-0002-8893-5240
Christophe CisarovskyMedical Oncology Service, Department of Oncology, Lausanne University Hospital, Lausanne, Switzerland.
Tatiana PetrovaLaboratory Vascular and Tumor Biology, Department on Oncology UNIL CHUV, Ludwig Institute for Cancer Research, Lausanne, Switzerland.
Laurent A DecosterdService and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Eva ChoongService and Laboratory of Clinical Pharmacology, Department of Laboratory Medicine and Pathology, Lausanne University Hospital and University of Lausanne, Lausanne, Switzerland.
Dan CelestiniSIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.
Michel A CuendetSIB Swiss Institute of Bioinformatics, Lausanne, Switzerland.ORCID http://orcid.org/0000-0002-0754-3425
Sarah BoughdadDepartment of Nuclear Medicine, Lausanne University Hospital, Lausanne, Switzerland.
John O PriorDepartment of Nuclear Medicine, Lausanne University Hospital, Lausanne, Switzerland.ORCID http://orcid.org/0000-0003-1429-1374
Jean-Yves MeuwlyDepartment of Radiology, Lausanne University Hospital, Lausanne, Switzerland.
William D FiggClinical Pharmacology Program, National Cancer Institute, Bethesda, MD, USA.ORCID http://orcid.org/0000-0003-2428-5613
Olivier MichielinDepartment of Oncology, Geneva University Hospitals, Geneva, Switzerland.
Serge LeyvrazCharité Comprehensive Cancer Center and Department of Hematology, Oncology and Tumor Immunology, Univeristätsmedizin, Berlin, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionSelective internal radiation therapy (SIRT) and sorafenib are used for patients with liver metastases from uveal melanoma. We conducted a phase I study to determine the optimal timing of administration of sorafenib in combination with radioembolisation.

methodsPatients received radioembolisation plus sorafenib initiated 14, 11, or 3 days after or 7 days before radioembolisation. The primary endpoint was safety. Secondary endpoints included efficacy and evaluation of circulating angiogenic factors. Sorafenib plasma levels were quantified retrospectively.

resultsTen patients received radioembolisation plus sorafenib. The most common grade 2-4 adverse events included rash, abdominal pain, fatigue and lymphocytopenia. Best response was partial response (30%) and stable disease (70%). Median progression-free and overall survival were 6.2 (4.8-not reached) and 11.7 months (9.4-not reached), respectively. Circulating angiogenic factors showed transient elevation at Day 10 post-SIRT when sorafenib was started 11-14 days after SIRT, but not when sorafenib was started before or just after SIRT. Most steady-state sorafenib plasma concentrations were in the upper percentiles relative to reference curves for single-agent sorafenib.

conclusionsSIRT plus sorafenib was feasible, but appeared more toxic than sorafenib alone, presumably due to altered pharmacokinetics. Sorafenib may hinder the angiogenic response when initiated before or shortly after SIRT. CLINICAL

trial registrationRegistry: ClinicalTrials.gov, NCT01893099.

Indexed as

Liver NeoplasmsMelanomaSorafenibUveal NeoplasmsYttrium RadioisotopesAdultAgedAntineoplastic AgentsFemaleHumansMaleMicrospheresMiddle AgedUveal MelanomaAntineoplastic AgentsSorafenibYttrium-90Yttrium Radioisotopes

Identifiers

PMID41381843
PMCPMC12858916

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.